DekaBank Deutsche Girozentrale’s Keros Therapeutics KROS Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,550	Closed	-$531K	–	1247
2025 Q4	$531K	Hold	7,550	–	–	﹤0.01%	989
2025 Q3	$525K	Hold	7,550	–	–	﹤0.01%	980
2025 Q2	$530K	Hold	7,550	–	–	﹤0.01%	974
2025 Q1	$489K	Hold	7,550	–	–	﹤0.01%	979
2024 Q4	$463K	Hold	7,550	–	–	﹤0.01%	1019
2024 Q3	$488K	Hold	7,550	–	–	﹤0.01%	1019
2024 Q2	$488K	Hold	7,550	–	–	﹤0.01%	1011
2024 Q1	$488K	Hold	7,550	–	–	﹤0.01%	1006
2023 Q4	$310K	Hold	7,550	–	–	﹤0.01%	1127
2023 Q3	$246K	Hold	7,550	–	–	﹤0.01%	1155
2023 Q2	$301K	Hold	7,550	–	–	﹤0.01%	1111
2023 Q1	$318K	Hold	7,550	–	–	﹤0.01%	1117
2022 Q4	$362K	Hold	7,550	–	–	﹤0.01%	1113
2022 Q3	$277K	Hold	7,550	–	–	﹤0.01%	1169
2022 Q2	$205K	Hold	7,550	–	–	﹤0.01%	1181
2022 Q1	$405K	Buy	7,550 +700	+10%	+$35.9K	﹤0.01%	1097
2021 Q4	$382K	Buy	6,850 +200	+3%	+$9.97K	﹤0.01%	1158
2021 Q3	$273K	Hold	6,650	–	–	﹤0.01%	1152
2021 Q2	$282K	Hold	6,650	–	–	﹤0.01%	1156
2021 Q1	$383K	Hold	6,650	–	–	﹤0.01%	1071
2020 Q4	$496K	Buy	+6,650	New	+$419K	﹤0.01%	1021

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

DekaBank Deutsche Girozentrale's KROS Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 7,550 shares — an estimated $531K sold.

DekaBank Deutsche Girozentrale first reported a position in KROS in Q4 2020 and held it in 21 quarters. The position peaked at $531K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 7,550 Keros Therapeutics shares in Q1 2026, an estimated $531K.
DekaBank Deutsche Girozentrale first reported a position in Keros Therapeutics in Q4 2020 and held it in 21 quarters.
DekaBank Deutsche Girozentrale's Keros Therapeutics position peaked at $531K in Q4 2025.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.